Epithelial ovarian cancer: A review of current management

Clinical Oncology

Volumn 17, Issue 6, 2005, Pages 399-411

  Guppy, A E ^a   Nathan, P D ^a   Rustin, Gordon J S ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Chemotherapy; Epidemiology; Epithelial ovarian cancer; Screening; Surgery

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; ESTROGEN; ETOPOSIDE; GANCICLOVIR; GEFITINIB; GEMCITABINE; INTERFERON; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE; THALIDOMIDE; THYMIDINE KINASE INHIBITOR; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG;

ADVANCED CANCER; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RELAPSE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG RESPONSE; ECHOGRAPHY; ESTROGEN THERAPY; FEMALE; FOLLOW UP; GENE MUTATION; GENE THERAPY; GENETIC RISK; HISTOPATHOLOGY; HUMAN; INCIDENCE; LAPAROTOMY; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PERITONEAL BIOPSY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TREATMENT PLANNING; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; FEMALE; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 23744456224     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.05.009     Document Type: Article

References (159)

1. A.P. Heintz F. Odicino P. Maisonneuve et al. Carcinoma of the ovary Int J Gynaecol Obstet 83 Suppl 1 2003 135-166
2. J. Ferlay F. Bray P. Pisani D. Parkin GLOBCAN 2000: Cancer incidence, mortality and prevalence worldwide 1 0 IARC Cancerbase 5 2001
3. SEER: Surveillance, Epidemiology, and End Results Program [computer program]. 2003.
4. A.S. Whittemore R. Harris J. Itnyre Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group Am J Epidemiol 136 1992 1212-1220
5. L. Rosenberg J.R. Palmer A.G. Zauber et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer Am J Epidemiol 139 1994 654-661
6. M.P. Vessey R. Painter Endometrial and ovarian cancer and oral contraceptives: Findings in a large cohort study Br J Cancer 71 1995 1340-1342
7. R.B. Ness J.A. Grisso J. Klapper et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions Am J Epidemiol 152 2000 233-241
8. S.E. Hankinson G.A. Colditz D.J. Hunter et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer Cancer 76 1995 284-290
9. D.F. Easton D. Ford D.T. Bishop Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Am J Hum Genet 56 1995 265-271
10. K. Bergfeldt B. Rydh F. Granath et al. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: A population-based cohort study Lancet 360 2002 891-894
11. P.P. Garg K. Kerlikowske L. Subak D. Grady Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis Obstet Gynecol 92 1998 472-479
12. C. Rodriguez A.V. Patel E.E. Calle E.J. Jacob M.J. Thun Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women JAMA 285 2001 1460-1465
13. G.L. Anderson H.L. Judd A.M. Kaunitz et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial JAMA 290 2003 1739-1748
14. D. Purdie A. Green C. Bain et al. Reproductive and other factors and risk of epithelial ovarian cancer: An Australian case - control study. Survey of Women's Health Study Group Int J Cancer 62 1995 678-684
15. H.A. Risch G.R. Howe Pelvic inflammatory disease and the risk of epithelial ovarian cancer Cancer Epidemiol Biomarkers Prev 4 1995 447-451
16. J.M. Schildkraut P.J. Schwingl E. Bastos A. Evanoff C. Hughes Epithelial ovarian cancer risk among women with polycystic ovary syndrome Obstet Gynecol 88 1996 554-559
17. D.C. Farrow N.S. Weiss J.L. Lyon J.R. Daling Association of obesity and ovarian cancer in a case - control study Am J Epidemiol 129 1989 1300-1304
18. C. La Vecchia A. Decarli E. Negri et al. Dietary factors and the risk of epithelial ovarian cancer J Natl Cancer Inst 79 1987 663-669
19. M. Huncharek J.F. Geschwind B. Kupelnick Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: A meta-analysis of 11,933 subjects from sixteen observational studies Anticancer Res 23 2003 1955-1960
20. A. Venn L. Watson F. Bruinsma G. Giles D. Healy Risk of cancer after use of fertility drugs with in-vitro fertilisation Lancet 354 1999 1586-1590
21. G.A. Omura M.F. Brady H.D. Homesley et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience J Clin Oncol 9 1991 1138-1150
22. V. Hess R. A'Hern N. Nasiri et al. Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment J Clin Oncol 22 2004 1040-1044
23. I. Vergote J. De Brabanter A. Fyles et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma Lancet 357 2001 176-182
24. I. Jacobs A.P. Davies J. Bridges et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography BMJ 306 1993 1030-1034
25. A.M. Ardekani L.A. Liotta E.F. Petricoin III Clinical potential of proteomics in the diagnosis of ovarian cancer Expert Rev Mol Diagn 2 2002 312-320
26. A. Antoniou P.D. Pharoah S. Narod et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies Am J Hum Genet 72 2003 1117-1130
27. J. Boyd Specific keynote: Hereditary ovarian cancer: What we know Gynecol Oncol 88 2003 S8-S10
28. W. Burke M. Daly J. Garber et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium JAMA 277 1997 997-1003
29. R. Hogg M. Friedlander Biology of epithelial ovarian cancer: implications for screening women at high genetic risk J Clin Oncol 22 2004 1315-1327
30. T.R. Rebbeck H.T. Lynch S.L. Neuhausen et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 2002 1616-1622
31. J.M. Niloff R.C. Knapp E. Schaetzl C. Reynolds R.C. Bast Jr. CA125 antigen levels in obstetric and gynecologic patients Obstet Gynecol 64 1984 703-707
32. R.C. Bast Jr. T.L. Klug E. St John et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N Engl J Med 309 1983 883-887
33. I. Jacobs D. Oram J. Fairbanks J. Turner C. Frost J.G. Grudzinskas A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer Br J Obstet Gynaecol 97 1990 922-929
34. A. Gadducci U. Baicchi R. Marrai M. Ferdeghini R. Bianchi V. Facchini Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses Gynecol Oncol 60 1996 197-202
35. R.P. Woolas M.R. Conaway F. Xu et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses Gynecol Oncol 59 1995 111-116
36. D. Grab F. Flock I. Stohr et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography Gynecol Oncol 77 2000 454-459
37. A.B. Kurtz J.V. Tsimikas C.M. Tempany et al. Diagnosis and staging of ovarian cancer: Comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis: analysis report of the Radiology Diagnostic Oncology Group Radiology 212 1999 19-27
38. G.J. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J Clin Oncol 21 2003 187-193
39. E.J. Junor D.J. Hole C.R. Gillis Management of ovarian cancer: Referral to a multidisciplinary team matters Br J Cancer 70 1994 363-370
40. J. Brugghe J.P. Baak E. Wiltshaw M. Brinkhuis G.A. Meijer C. Fisher Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment Gynecol Oncol 68 1998 47-53
41. F. Nagele E. Petru M. Medl C. Kainz A.H. Graf P. Sevelda Preoperative CA 125: An independent prognostic factor in patients with stage I epithelial ovarian cancer Obstet Gynecol 86 1995 259-264
42. C. Trope J. Kaern T. Hogberg et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument Ann Oncol 11 2000 281-288
43. J.B. Trimbos I. Vergote G. Bolis et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial J Natl Cancer Inst 95 2003 113-125
44. J.M. Schilder A.M. Thompson P.D. DePriest et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy Gynecol Oncol 87 2002 1-7
45. G. Zanetta S. Chiari S. Rota et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age Br J Obstet Gynaecol 104 1997 1030-1035
46. R.C. Young L.A. Walton S.S. Ellenberg et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials N Engl J Med 322 1990 1021-1027
47. F.Y. Ahmed E. Wiltshaw R.P. A'Hern B. Nicol J. Shepherd P. Blake et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma J Clin Oncol 14 1996 2968-2975
48. N. Colombo D. Guthrie S. Chiari et al. International Collaborative Ovarian Neoplasm trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer J Natl Cancer Inst 95 2003 125-132
49. A. Martinez M.F. Schray A.E. Howes M.A. Bagshaw Postoperative radiation therapy for epithelial ovarian cancer: The curative role based on a 24-year experience J Clin Oncol 3 1985 901-911
50. I.B. Vergote L.N. Vergote-De Vos V.M. Abeler et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer Cancer 69 1992 741-749
51. R.C. Young M.F. Brady R.K. Nieberg et al. Adjuvant treatment for early ovarian cancer: A randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin: A gynecologic oncology group study J Clin Oncol 21 2003 4350-4355
52. C.T. Griffiths Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl Cancer Inst Monogr 42 1975 101-104
53. W.J. Hoskins B.N. Bundy J.T. Thigpen G.A. Omura The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study Gynecol Oncol 47 1992 159-166
54. E.W. Munnell The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952-1961 Am J Obstet Gynecol 100 1968 790-805
55. R.E. Bristow R.S. Tomacruz D.K. Armstrong E.L. Trimble F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis J Clin Oncol 20 2002 1248-1259
56. E.J. Junor D.J. Hole L. McNulty M. Mason J. Young Specialist gynaecologists and survival outcome in ovarian cancer: A Scottish national study of 1866 patients Br J Obstet Gynaecol 106 1999 1130-1136
57. P.E. Schwartz T.J. Rutherford J.T. Chambers E.I. Kohorn R.P. Thiel Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival Gynecol Oncol 72 1999 93-99
58. I. Vergote I. De W W. Tjalma M. Van Gramberen J. Decloedt P. van Dam Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients Gynecol Oncol 71 1998 431-436
59. M.E. van der Burg M. van Lent M. Buyse et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer N Engl J Med 332 1995 629-634
60. P.G. Rose S. Nerenstone M.F. Brady D. Clarke-Pearson G. Olt S. Rubin A phase III randomised study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: A Gynecologic Oncology Group study [abstract 802] Proc Am Soc Clin Oncol 2002 21
61. M.L. Berman Future directions in the surgical management of ovarian cancer Gynecol Oncol 90 2003 S33-S39
62. S.C. Dowdy C.L. Constantinou L.C. Hartmann et al. Long-term follow-up of women with ovarian cancer after positive second-look laparotomy Gynecol Oncol 91 2003 563-568
63. S.C. Rubin T.C. Randall K.A. Armstrong D.S. Chi W.J. Hoskins Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings Obstet Gynecol 93 1999 21-24
64. G. Omura J.A. Blessing C.E. Ehrlich et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study Cancer 57 1986 1725-1730
65. C.J. Williams G.M. Mead F.R. Macbeth et al. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: Mature results of a randomized trial J Clin Oncol 3 1985 1455-1462
66. K. Aabo M. Adams P. Adnitt et al. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group Br J Cancer 78 1998 1479-1487
67. R.F. Ozols B.N. Bundy B.E. Greer et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study J Clin Oncol 21 2003 3194-3200
68. A. du Bois H.J. Luck W. Meier et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320-1329
69. D.S. Alberts S. Green E.V. Hannigan et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer J Clin Oncol 10 1992 706-717
70. K. Swenerton J. Jeffrey G. Stuart et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 10 1992 718-726
71. S.B. Kaye J. Paul J. Cassidy et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group J Clin Oncol 14 1996 2113-2119
72. W.P. McGuire W.J. Hoskins M.F. Brady et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study J Clin Oncol 13 1995 1589-1599
73. M. Gore P. Mainwaring R. A'Hern et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group J Clin Oncol 16 1998 2426-2434
74. H.E. Lambert G.J. Rustin W.M. Gregory A.E. Nelstrop A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study Ann Oncol 8 1997 327-333
75. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. The Ovarian Cancer Meta-Analysis Project J Clin Oncol 9 1991 1668-1674
76. ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study Lancet 352 1998 1571-1576
77. W.P. McGuire W.J. Hoskins M.F. Brady et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1-6
78. M.J. Piccart K. Bertelsen K. James et al. Randomized intergroup trial of cisplatin - paclitaxel versus cisplatin - cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results J Natl Cancer Inst 92 2000 699-708
79. F.M. Muggia P.S. Braly M.F. Brady et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study J Clin Oncol 18 2000 106-115
80. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial Lancet 360 2002 505-515
81. NICE Guidance on the use of paclitaxel in the treatment of ovarian cancer 2003 National Institute of Clinical Excellence Technology Appraisal Guidance p. 55
82. Y. Aoki T. Sato I. Tsuneki M. Watanabe et al. Docetaxel in combination with carboplatin for chemo-naive patients with epithelial ovarian cancer Int J Gynecol Cancer 12 2002 704-709
83. M. Markman A. Kennedy K. Webster G. Peterson B. Kulp J. Belinson Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum J Clin Oncol 19 2001 1901-1905
84. D.A. Vorobiof B.L. Rapoport M.R. Chasen G.L. Cohen R. Mahomed M. Karime Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy Int J Gynecol Cancer 13 2003 287-291
85. P.A. Vasey Survival and longer-term toxicity results from the SCOTROC study; docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC) [abstract 804] Proc Am Soc Clin Oncol 21 2002 201a
86. T.C. Chou R.J. Motzer Y. Tong G.J. Bosl Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design J Natl Cancer Inst 86 1994 1517-1524
87. G.J. Peters A.M. Bergman V. Ruiz vH G. Veerman C.M. Kuiper B.J. Braakhuis Interaction between cisplatin and gemcitabine in vitro and in vivo Semin Oncol 22 1995 72-79
88. S.W. Hansen H. Anderson K. Boman et al. Gemcitabine, carboplatin and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV [abstract 1379] Proc Am Soc Clin Oncol 1999
89. Look KY, Bookman MA, Brady MF, Schol J, Herzog t, Rocerto TF. An update of the phase I feasibility trial of carboplatin, paclitaxel and gemcitabine in patients with previously untreated epithelial ovarian cancer or primary peritoneal cancer (EOC/PPC): A Gynecologic Oncology Group (GOG) study. Proceeding of the 32nd Annual meeting of the society of Gynecologic Oncologists 2001.
90. J. Pfisterer A. Lortholary R. Kimmig B.L. Weber B.A. du H. Bourgeois Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIb-IV. Interim results of a gynecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO [abstract 1793] Proc Am Soc Clin Oncol 22 2003 446
91. du Bois A, Combe M, Rochon J, Jackisch C, Malaurie M, Lueck HJ. Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial [abstract 5007]. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22:14S.
92. G.B. Kristensen I. Vergote G. Stuart et al. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin Int J Gynecol Cancer 13 Suppl 2 2003 172-177
93. G.J. Rustin R.J. Atkinson R.J. Osborne D. Parkin J. Paul P. Symonds Preliminary results of SCOTROC 2A, a randomised feasibility study of carboplatin then sequential docetaxel or two schedules of docetaxel + gemcitabine in ovarian/mullarian cancers [abstract 810] Proc Am Soc Clin Oncol 2002 21a
94. A.E. Guppy A.E. Nelstrop T. Foster R. Agarwal M.J. Seckl G.J. Rustin A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer Br J Cancer 90 2004 810-814
95. J.A. Ledermann R. Herd D. Maraninchi et al. High-dose chemotherapy for ovarian carcinoma: Long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT) Ann Oncol 12 2001 693-699
96. H. Cure C. Battista J. Guastalla Phase III randomised trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients with responsive low-burden advanced ovarian cancer (AOC): Preliminary results of a GINECO/FN-CLCC/SFGM-TC study Proc Am Soc Clin Oncol 20 2001 204a
97. H. Goldberg M.E. Stein M. Steiner E. Sprecher D. Beck A. Kuten Consolidation radiation therapy following cytoreductive surgery, chemotherapy and second-look laparotomy for epithelial ovarian carcinoma: Long-term follow-up Tumori 87 2001 248-251
98. H.E. Lambert G.J. Rustin W.M. Gregory A.E. Nelstrop A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: A North Thames Ovary Group study J Clin Oncol 11 1993 440-448
99. F. Lawton D. Luesley G. Blackledge et al. A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II Clin Oncol 2 1990 4-9
100. M.J. Piccart A. Floquet G. Scarfone et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy Int J Gynecol Cancer 13 Suppl 2 2003 196-203
101. M.A. Varia F.B. Stehman B.N. Bundy et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: A randomized trial of the Gynecologic Oncology Group J Clin Oncol 21 2003 2849-2855
102. Seiden M, Benigno B. A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC) [abstract 5008]. 2004 ASCO Annual Meetings Proceedings (Post-meeting Edition) 2004;22:14S.
103. A.A. Epenetos V. Hird H. Lambert P. Mason C. Coulter Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy Int J Gynecol Cancer 10 2000 44-46
104. M.L. Rothenberg P.Y. Liu S. Wilczynski E.V. Hannigan et al. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: A Southwest Oncology Group trial (SWOG-9326) Gynecol Oncol 82 2001 317-322
105. M. Markman T. Glass H.O. Smith et al. Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: A Southwest Oncology Group trial Gynecol Oncol 88 2003 282-288
106. T.B. Hakes E. Chalas W.J. Hoskins W.B. Jones M. Markman S.C. Rubin et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma Gynecol Oncol 45 1992 284-289
107. J.L. Perez-Gracia E.M. Carrasco Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: Systematic review of the literature and implications for future research Gynecol Oncol 84 2002 201-209
108. G. Hall R. Coleman M. Stead Maintenance therapy with interferon for advanced ovarian cancer [abstract 1529] Proc Am Soc Clin Oncol 19 2000 386a
109. M. Markman P.Y. Liu S. Wilczynski et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial J Clin Oncol 21 2003 2460-2465
110. M. Markman Intraperitoneal antineoplastic drug delivery: Rationale and results Lancet Oncol 4 2003 277-283
111. D.S. Alberts P.Y. Liu E.V. Hannigan et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 1996 1950-1955
112. A. Gadducci F. Carnino S. Chiara et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: A randomized trial of the Gruppo Oncologico Nord-Ovest Gynecol Oncol 76 2000 157-162
113. S. Kirmani P.S. Braly E.F. McClay et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer Gynecol Oncol 54 1994 338-344
114. M. Markman B.N. Bundy D.S. Alberts et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 2001 1001-1007
115. A. Polyzos N. Tsavaris C. Kosmas et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer Oncology 56 1999 291-296
116. M.S. Yen C.M. Juang C.R. Lai G.C. Chao H.T. Ng C.C. Yuan Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer Int J Gynaecol Obstet 72 2001 55-60
117. G.J. Rustin A.E. Nelstrop M.K. Tuxen H.E. Lambert Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group Study Ann Oncol 7 1996 361-364
118. I. Vergote G.J. Rustin E.A. Eisenhauer et al. Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup J Natl Cancer Inst 92 2000 1534-1535
119. R.E. Bristow M.G. del Carmen H.K. Pannu et al. Clinically occult recurrent ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT Gynecol Oncol 90 2003 519-528
120. G.J. Rustin A.E. Nelstrop P. McClean et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 J Clin Oncol 14 1996 1545-1551
121. M.E. van der Burg F.B. Lammes J. Verweij The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer Ann Oncol 1 1990 301-302
122. E.A. Eisenhauer J.B. Vermorken M. Van Glabbeke Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients [see comments] Ann Oncol 8 1997 963-968
123. R.A. Segna P.R. Dottino J.P. Mandeli K. Konsker C.J. Cohen Secondary cytoreduction for ovarian cancer following cisplatin therapy J Clin Oncol 11 1993 434-439
124. E.H. Tay P.T. Grant V. Gebski N.F. Hacker Secondary cytoreductive surgery for recurrent epithelial ovarian cancer Obstet Gynecol 99 2002 1008-1013
125. Feuer D, Broadley K. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. In: The Cochrame Library, Issue 3. Oxford: Update Software, 2003.
126. G. Blackledge F. Lawton C. Redman K. Kelly Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials Br J Cancer 59 1989 650-653
127. M. Markman B. Reichman T. Hakes et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin J Clin Oncol 9 1991 1801-1805
128. M. Gore Treatment of relapsed ovarian cancer The American Society of Clinical Oncology Educational Book 2001 p. 468-476
129. G.J. Rustin M. Quinn T. Thigpen et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) J Natl Cancer Inst 96 2004 487-488
130. P. Therasse Evaluation of response: New and standard criteria Ann Oncol 13 Suppl 4 2002 127-129
131. M.K. Parmar J.A. Ledermann N. Colombo et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/ AGO-OVAR-2.2 trial Lancet 361 2003 2099-2106
132. M.G. Cantu A. Buda G. Parma et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens J Clin Oncol 20 2002 1232-1237
133. G. Bolis G. Scarfone G. Giardina et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer Gynecol Oncol 81 2001 3-9
134. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG [abstract 5005]. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22:14S.
135. J. Kavanagh D. Tresukosol C. Edwards et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer J Clin Oncol 13 1995 1584-1588
136. H.W. ten Bokkel M. Gore J. Carmichael et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J Clin Oncol 15 1997 2183-2193
137. A.N. Gordon J.T. Fleagle D. Guthrie D.E. Parkin M.E. Gore A.J. Lacave Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312-3322
138. T. Meyer A.E. Nelstrop M. Mahmoudi G.J. Rustin Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer Ann Oncol 12 2001 1705-1709
139. M.E. van der Burg R. de Wit W.L. van Putten A. Logmans W.H. Kruit G. Stoter et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer Br J Cancer 86 2002 19-25
140. K. Munstedt J. Steen A.G. Knauf T. Buch R. von Georgi F.E. Franke Steroid hormone receptors and long term survival in invasive ovarian cancer Cancer 89 2000 1783-1791
141. C.J. Williams I. Simera Tamoxifen for relapse of ovarian cancer The Cochrane Library, Issue 3 2003 Update software Oxford
142. K.D. Hatch J.B. Beecham J.A. Blessing W.T. Creasman Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic oncology group study of second-line therapy in 105 patients Cancer 68 1991 269-271
143. B.W. Yin K.O. Lloyd Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16 J Biol Chem 276 2001 27371-27375
144. U. Wagner S. Kohler S. Reinartz et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment See The biology behind: K.A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin Cancer Res 7 2001 1112-1115. Clin Cancer Res 7 2001 1154-1162
145. Nicholson S, Bell S, McCormack M. et al. A randomised phase III trial of adjuvant Intraperitoneal Radioimmunotherapy in Ovarian cancer [abstract 1514]. 2000 ASCO Annual Meeting Proceedings.
146. J.J. Hernando T.W. Park K. Kubler R. Offergeld H. Schlebusch T. Bauknecht Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: Clinical and immunological evaluation of a phase I trial Cancer Immunol Immunother 51 2002 45-52
147. S. Fen Wen V. Mahavni E. Quijano J. Shinoda M. Grace I. Runnenbaum Evidence of p53 gene transfer and its biological activities in ovarian cancer patients receiving multiple cycles of recombinant adenovirus expressing wild-type p53 Proc Am Soc Clin Oncol 20 2001
148. A.G. Zeimet C. Marth Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 4 2003 415-422
149. P.A. Vasey L.N. Shulman S. Campos J. Davis M. Gore S. Johnston et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer J Clin Oncol 20 2002 1562-1569
150. S.M. Freeman C.N. Abboud K.A. Whartenby et al. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified Cancer Res 53 1993 5274-5283
151. N. Finkler A. Gordon M. Crozier R. Edwards J. Figueroa A. Garcia Phase 2 evaluation of OS!-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma [abstract 831] Proc Am Soc Clin Oncol 20 2001
152. J.M. Sewell K.G. Macleod A. Ritchie J.F. Smyth S.P. Langdon Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa") Br J Cancer 86 2002 456-462
153. M.A. Bookman K.M. Darcy D. Clarke-Pearson R.A. Boothby I.R. Horowitz Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group J Clin Oncol 21 2003 283-290
154. L. Hu J. Hofmann C. Zaloudek N. Ferrara T. Hamilton R.B. Jaffe Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer Am J Pathol 161 2002 1917-1924
155. L. Rosano F. Spinella D. Salani et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma Cancer Res 63 2003 2447-2453
156. A.D. Laird P. Vajkoczy L.K. Shawver et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors Cancer Res 60 2000 4152-4160
157. N. Abramson P.K. Stokes M. Luke A.R. Marks J.M. Harris Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide J Clin Oncol 20 2002 1147-1149
158. T. Eisen C. Boshoff I. Mak et al. Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer Br J Cancer 82 2000 812-817
159. P.G. Rose J.A. Blessing J.T. Soper J.F. Barter Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study J Clin Oncol 16 1998 405-410